Skip to main content
SpringerLink
Log in

Ocular Plaque Brachytherapy for Uveal Melanoma and Retinoblastoma

  • Chapter
  • First Online:
Brachytherapy

  • 838 Accesses

Abstract

The main topic of this chapter is brachytherapy for ocular tumor. A small dish-shaped applicator is temporarily attached outside of the eyeball where the tumor is located, and after adequate irradiation time, it is removed. Because generally eyeball moves quickly and frequently, it is difficult to irradiate intraocular tumor with external beam technique. When big dose is delivered with adequate margin to compensate the organ motion, it is difficult to preserve visual function. On the other hand, when the applicator is accurately attached to the location of the tumor, the applicator moves together with the eyeball, and it is possible to perform very conformal irradiation. Therefore, ocular plaque brachytherapy is very important for the management of ocular tumors such as uveal melanoma and retinoblastoma.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 159.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Singh AD, Turell ME, Topham AK. Uveal melanoma: trends in incidence, treatment, and survival. Ophthalmology. 2011;118:1881–5.

    Article  PubMed  Google Scholar 

  2. Hu DN, Yu GP, McCormick SA, et al. Population based incidence of uveal melanoma in various races and ethnic groups. Am J Ophthalmol. 1996;76:784–96.

    Google Scholar 

  3. Kaneko A. Incidence of malignant melanoma of the eye in Japan, 1977–1979. Nippon Ganka Gakkai Zasshi. 1982;86:1042–5.

    PubMed  CAS  Google Scholar 

  4. Diener-West M, Reynolds SM, Agugliaro DJ, et al. Development of metastatic disease after enrollment in the COMS trials for treatment of choroidal melanoma: collaborative ocular melanoma study group report no 26. Arch Ophthalmol. 2005;123:1639–43.

    Article  PubMed  Google Scholar 

  5. Mainster MA, Turner PL. Ultraviolet-B phototoxicity and hypothetical photomelanomagenesis: intraocular and crystalline lens photoprotection. Am J Ophthalmol. 2010;149:543–9.

    Article  CAS  PubMed  Google Scholar 

  6. Shields CL, Furuta M, Berman EL, et al. Choroidal nevus transformation into melanoma:analysis of 2514 consecutive cases. Arch Ophthalmol. 2009;127:981–7.

    Article  PubMed  Google Scholar 

  7. Collaborative Ocular Melanoma Study Group. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma: V. Twelve-year mortality rates and prognostic factors: COMS report no 28. Arch Ophthalmol. 2006;124:1684–93.

    Article  Google Scholar 

  8. Hawkins BS, Collaborative Ocular Melanoma Study Group. The collaborative ocular melanoma study (COMS) randomized trial of pre-enucleation radiation of large choroidal melanoma: IV. Ten-year mortality findings and prognostic factors. COMS report number 24. Am J Ophthalmol. 2004;138:936–51.

    Article  PubMed  Google Scholar 

  9. The Collaborative Ocular Melanoma Study Group. Factors predictive of growth and treatment of small choroidal melanoma:COMS report no. 5. Arch Ophthalmol. 1997;115:1537–44.

    Article  Google Scholar 

  10. The Collaborative Ocular Melanoma Study Group. Accuracy of diagnosis of choroidal melanomas in the collaborative ocular melanoma study. COMS report no. 1. Arch Ophthalmol. 1990;108:1268–73.

    Article  Google Scholar 

  11. Sandinha MT, Farquharson MA. McKay IC et al: Monosomy 3 predicts death but not time until death in choroidal melanoma. Invest Ophthalmol Vis Sci. 2005;46:3497–501.

    Article  PubMed  Google Scholar 

  12. Gupta MP, Lane AM, DeAngelis MM, et al. Clinical characteristics of uveal melanoma in patients with germline BAP1 mutations. JAMA Ophthalmol. 2015;133:881–7.

    Article  PubMed  Google Scholar 

  13. Plasseraud KM, Cook RW, Tsai T, et al. Clinical performance and management outcomes with the DecisionDx-UM gene expression profile test in a prospective multicenter study. J Oncol. 2016;2016:5325762.

    Article  PubMed  PubMed Central  Google Scholar 

  14. American Brachytherapy Society–Ophthalmic Oncology Task Force. The American brachytherapy society consensus guidelines for plaque brachytherapy of uveal melanoma and retinoblastoma. Brachytherapy. 2014;13:1–14.

    Article  Google Scholar 

  15. Melia M, Moy CS, Reynolds SM, et al. Quality of life after iodine 125 brachytherapy vs enucleation for choroidal melanoma: 5-year results from the collaborative ocular melanoma study: COMS QOLS report no. 3. Arch Ophthalmol. 2006;124:226–38.

    Article  PubMed  Google Scholar 

  16. Collaborative Ocular Melanoma Study Group. Collaborative ocular melanoma study (COMS) randomized trial of I-125 brachytherapy for medium choroidal melanoma, I: visual acuity 3 years following I-125 brachytherapy for choroidal melanoma: COMS report no. 16. Ophthalmology. 2001;108:348–66.

    Article  Google Scholar 

  17. Toyama S, Tsuji H, Mizoguchi N, et al. Long-term results of carbon ion radiation therapy for locally advanced or unfavorably located choroidal melanoma: usefulness of CT-based 2-port orthogonal therapy for reducing the incidence of neovascular glaucoma. Int J Radiat Oncol Biol Phys. 2013;86:270–6.

    Article  PubMed  Google Scholar 

  18. Survival rate and risk factors for patients with retinoblastoma in Japan. The Committee for the National Registry of retinoblastoma. Jpn J Ophthalmol. 1992;36:121–31.

    Google Scholar 

  19. Shields CL, De Potter P, Himelstein BP, et al. Chemoreduction in the initial management of intraocular retinoblastoma. Arch Ophthalmol. 1996;114:1330–8.

    Article  CAS  PubMed  Google Scholar 

  20. Shields CL, Mashayekhi A, Au AK, et al. The international classification of retinoblastoma predicts chemoreduction success. Ophthalmology. 2006;113:2276–80.

    Article  PubMed  Google Scholar 

  21. Brierley JD, Gospodarowicz MK, Wittekind C. TNM classification of malignant tumors. 8th ed. Hoboken, New Jersey: Wiley-Blackwell; 2017. 978-1-119-26357-9

    Google Scholar 

  22. Schueler AO, Fluhs D, Anastassiou G, et al. Beta-ray brachytherapy with 106Ru plaques for retinoblastoma. Int J Radiat Oncol Biol Phys. 2006;64:1212–21.

    Article  Google Scholar 

  23. Shields CL, Shields JA. Retinoblastoma management: advances in enucleation, intravenous chemoreduction, and intra-arterial chemotherapy. Curr Opin Ophthalmol. 2010;21:203–12.

    Article  PubMed  Google Scholar 

  24. Suzuki S, Yamane T, Mohri M, et al. Selective ophthalmic arterial injection therapy for intraocular retinoblastoma: the long-term prognosis. Ophthalmology. 2011;118:2081–7.

    Article  PubMed  Google Scholar 

  25. Murakami N, Suzuki S, Ito Y, et al. 106Ruthenium plaque therapy (RPT) for retinoblastoma. Int J Radiat Oncol Biol Phys. 2012;84:59–65.

    Article  PubMed  Google Scholar 

  26. Krema H, Xu W, Payne D, et al. Factors predictive of radiation retinopathy post 125 iodine brachytherapy for uveal melanoma. Can J Ophthalmol. 2011;46:158–63.

    Article  PubMed  Google Scholar 

  27. Moore R. Choroidal sarcoma treated by the intraocular insertion of radon seeds. Br J Ophthalmol. 1930;14:145e156.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Radiation Oncology, National Cancer Center Hospital, Tokyo, Japan

    Naoya Murakami & Jun Itami

  2. Department of Ophthalmic Oncology, National Cancer Center Hospital, Tokyo, Japan

    Shigenobu Suzuki

Authors
  1. Naoya Murakami
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shigenobu Suzuki
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jun Itami
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Radiation Oncology Department, The Cancer Institute Hospital of JFCR, Koto-ku, Tokyo, Japan

    Yasuo Yoshioka

  2. Department of Radiation Oncology, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan

    Jun Itami

  3. Radiation Oncology Department, The Cancer Institute Hospital of JFCR, Koto-ku, Tokyo, Japan

    Masahiko Oguchi

  4. Department of Radiation Oncology, Gunma University, Maebashi, Gunma, Japan

    Takashi Nakano

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Singapore Pte Ltd.

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Murakami, N., Suzuki, S., Itami, J. (2019). Ocular Plaque Brachytherapy for Uveal Melanoma and Retinoblastoma. In: Yoshioka, Y., Itami, J., Oguchi, M., Nakano, T. (eds) Brachytherapy. Springer, Singapore. https://doi.org/10.1007/978-981-13-0490-3_19

Download citation

  • DOI: https://doi.org/10.1007/978-981-13-0490-3_19

  • Published:

  • Publisher Name: Springer, Singapore

  • Print ISBN: 978-981-13-0489-7

  • Online ISBN: 978-981-13-0490-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation